Cevimeline

Cevimeline

Systematic (IUPAC) name
2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
Clinical data
Trade names	Evoxac
AHFS/Drugs.com	monograph
MedlinePlus	a608025
Pregnancy category	C
Legal status	℞ (Prescription only)
Routes of administration	Oral
Pharmacokinetic data
Protein binding	< 20%
Identifiers
CAS Number	107233-08-9 Y
ATC code	N07AX03 (WHO)
PubChem	CID: 83898
DrugBank	DB00185 Y
ChemSpider	75707 Y
UNII	K9V0CDQ56E Y
KEGG	D07667 Y
ChEBI	CHEBI:3568 N
ChEMBL	CHEMBL1201267 N
Chemical data
Formula	C10H17NOS
Molecular mass	199.31308 g/mol
SMILES O1[C@H](SC[C@@]12CN3CCC2CC3)C
InChI InChI=1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m1/s1 Y Key:WUTYZMFRCNBCHQ-PSASIEDQSA-N Y
NY (what is this?)  (verify)

Cevimeline (Evoxac) is a parasympathomimetic and muscarinic agonist, with particular effect on M₁ and M₃ receptors. It is used in the treatment of dry mouth and especially associated with Sjögren's syndrome.

Mechanism of action

By activating the M₃ receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.

Side effects

Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping.

Contraindications include asthma and angle closure glaucoma.

See also

• Pilocarpine - a similar parasympathomimetic medication for dry mouth (Xerostomia)
• Bethanechol - a similar muscarinic parasympathomimetic with longer lasting effect

External links

• Evoxac website